{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:25:26Z","timestamp":1787030726524,"version":"build-2736575974"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Vasculitic neuropathy (VN) is a diverse group of immune-mediated peripheral neuropathies that result in systemic or non-systemic vasculitic neuropathy. There are limited studies that characterize the neurological outcome of VN patients. We aimed to describe the clinical features, diagnostic workup, and neurological outcomes of VN patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We retrospectively reviewed adults with VN evaluated at the Hospital of the University of Pennsylvania between October 2020 and December 2025. Diagnostic classification followed the Peripheral Nerve Society 2010 criteria and the 2022 American College of Rheumatology\/European Alliance of Associations for Rheumatology classification criteria for systemic vasculitides. Definite vasculitis was defined by biopsy confirmation or fulfillment of formal classification criteria; probable vasculitis was supported by clinical, electrodiagnostic, and serologic features. Neurological impairment was quantified using the Neuropathy Impairment Score (NIS). Improvement was defined\n                      <jats:italic>a priori<\/jats:italic>\n                      as a decrease in NIS of at least 2 points (\u0394NIS \u2264\u202f\u2212\u202f2). Continuous variables were compared using Welch two-sample\n                      <jats:italic>t<\/jats:italic>\n                      -tests; categorical variables using Fisher exact tests.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 85 patients, 66 met inclusion criteria. Non-systemic disease was analyzed as two distinct entities, the NSVN subtype (\n                      <jats:italic>n<\/jats:italic>\n                      \u202f=\u202f18, 27.3%) and lumbosacral radiculoplexus neuropathy (LRPN;\n                      <jats:italic>n<\/jats:italic>\n                      \u202f=\u202f15, 13 diabetic and 2 non-diabetic), alongside systemic vasculitic neuropathy (\n                      <jats:italic>n<\/jats:italic>\n                      \u202f=\u202f33). The most common subtypes were the NSVN subtype (27.3%), ANCA-associated vasculitis (22.7%), and diabetic LRPN (19.7%). Biopsy was performed in 48 patients and demonstrated vasculitis in 41; the remaining patients met criteria for possible vasculitic neuropathy on clinical, electrodiagnostic, and serologic grounds (59 definite, 7 possible overall). Over a median follow-up of 13.5\u202fmonths (IQR 6.2\u201331.2), 39 patients (59.1%) improved by \u2265 2 NIS points, 5 (7.6%) were stable, and 22 (33.3%) worsened. Patients who improved had higher baseline NIS-motor subscores (17.3\u202f\u00b1\u202f14.6 vs. 6.7\u202f\u00b1\u202f7.9,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.001) and shorter diagnostic delays (12.3\u202f\u00b1\u202f16.4 vs. 30.3\u202f\u00b1\u202f41.7\u202fmonths,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.042).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Majority of patients experienced neurological improvement on the NIS. Greater baseline motor impairment and shorter diagnostic delay were associated with improvement. These findings characterize the clinical course of VN in a contemporary tertiary-care setting and provide a benchmark for future multicenter studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2026.1886100","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:28:49Z","timestamp":1787027329000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Vasculitic neuropathy: clinical features, diagnostic approach, and neurological outcomes in a single-center cohort"],"prefix":"10.3389","volume":"17","author":[{"given":"Sevinch","family":"Rakhmonova","sequence":"first","affiliation":[{"name":"Department of Neurology, Perelman School of Medicine, University of Pennsylvania","place":["Philadelphia, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chafic","family":"Karam","sequence":"additional","affiliation":[{"name":"Department of Neurology, Perelman School of Medicine, University of Pennsylvania","place":["Philadelphia, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 revised international Chapel Hill consensus conference nomenclature of Vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S1474-4422(13)70236-9","article-title":"Vasculitic neuropathies","volume":"13","author":"Gwathmey","year":"2014","journal-title":"Lancet Neurol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/nrneurol.2017.42","article-title":"The nonsystemic vasculitic neuropathies","volume":"13","author":"Collins","year":"2017","journal-title":"Nat Rev Neurol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/j.1529-8027.2010.00281.x","article-title":"Peripheral Nerve Society Guideline on the classification, diagnosis, investigation, and immunosuppressive therapy of non-systemic vasculitic neuropathy: executive summary","volume":"15","author":"Collins","year":"2010","journal-title":"J Peripher Nerv Syst"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1136\/annrheumdis-2021-221795","article-title":"2022 American College of Rheumatology\/European Alliance of associations for rheumatology classification criteria for granulomatosis with polyangiitis","volume":"81","author":"Robson","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1136\/annrheumdis-2021-221796","article-title":"2022 American College of Rheumatology\/European Alliance of associations for rheumatology classification criteria for microscopic polyangiitis","volume":"81","author":"Suppiah","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1136\/annrheumdis-2021-221794","article-title":"2022 American College of Rheumatology\/European Alliance of associations for rheumatology classification criteria for eosinophilic granulomatosis with polyangiitis","volume":"81","author":"Grayson","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1212\/wnl.53.9.2113","article-title":"Microvasculitis and ischemia in diabetic lumbosacral radiculoplexus neuropathy","volume":"53","author":"Dyck","year":"1999","journal-title":"Neurology"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1093\/brain\/124.6.1197","article-title":"Non-diabetic lumbosacral radiculoplexus neuropathy: natural history, outcome and comparison with the diabetic variety","volume":"124","author":"Dyck","year":"2001","journal-title":"Brain"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"e2098","DOI":"10.1212\/WNL.0000000000011799","article-title":"Lumbosacral Radiculoplexus neuropathy: neurologic outcomes and survival in a population-based study","volume":"96","author":"Pinto","year":"2021","journal-title":"Neurology"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"e210141","DOI":"10.1212\/WNL.0000000000210141","article-title":"Vasculitic myopathy: clinical characteristics and long-term outcomes","volume":"103","author":"Pinto","year":"2024","journal-title":"Neurology"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"102874","DOI":"10.1016\/j.autrev.2021.102874","article-title":"Nonsystemic vasculitic neuropathy: presentation and long-term outcome from a French cohort of 50 patients","volume":"20","author":"Quirins","year":"2021","journal-title":"Autoimmun Rev"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1212\/wnl.42.6.1164","article-title":"The Rochester Diabetic Neuropathy Study: reassessment of tests and criteria for diagnosis and staged severity","volume":"42","author":"Dyck","year":"1992","journal-title":"Neurology"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/qjmed\/hcl125","article-title":"Treatment of vasculitic peripheral neuropathy: a retrospective analysis of outcome","volume":"100","author":"Mathew","year":"2007","journal-title":"QJM"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/mus.27004","article-title":"Establishing standards for acceptable waveforms in nerve conduction studies","volume":"62","year":"2020","journal-title":"Muscle Nerve"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1002\/sim.7992","article-title":"Minimum sample size for developing a multivariable prediction model: PART II - binary and time-to-event outcomes","volume":"38","author":"Riley","year":"2019","journal-title":"Stat Med"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1212\/CON.0000000000000917","article-title":"Peripheral neuropathies associated with Vasculitis and autoimmune connective tissue disease","volume":"26","author":"Karam","year":"2020","journal-title":"Continuum (Minneap Minn)"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.clinph.2010.06.024","article-title":"Clinical consequences of reinnervation disorders after focal peripheral nerve lesions","volume":"122","author":"Valls-Sole","year":"2011","journal-title":"Clin Neurophysiol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"4496","DOI":"10.4103\/jfmpc.jfmpc_2480_21","article-title":"Nerve biopsies in patients with peripheral neuropathy: a prospective evaluation","volume":"11","author":"Agrawal","year":"2022","journal-title":"J Family Med Prim Care"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1886100\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:28:50Z","timestamp":1787027330000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1886100\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":19,"alternative-id":["10.3389\/fneur.2026.1886100"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2026.1886100","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]},"article-number":"1886100"}}